Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 8 |
| List of Tables | 5 | 3 |
| List of Figures | 8 | 3 |
| Musculoskeletal Disorders Therapeutics Market to 2017 -Introduction | 11 | 2 |
| GBI Research Report Guidance | 11 | 2 |
| Musculoskeletal Disorders Therapeutics Market to 2017 - Market Overview | 13 | 7 |
| Introduction | 13 | 1 |
| Revenue | 13 | 1 |
| Annual Cost of Treatment | 14 | 1 |
| Treatment Usage Pattern | 15 | 1 |
| Diseased Population | 16 | 1 |
| Treatment Seeking Population | 17 | 1 |
| Diagnosed Population | 18 | 1 |
| Prescription Population | 19 | 1 |
| Musculoskeletal Disorders Therapeutics Market to 2017 -Geographical Landscape | 20 | 17 |
| Revenue Analysis by Geography | 20 | 2 |
| The US | 22 | 1 |
| Revenue | 22 | 1 |
| Annual Cost of Treatment | 23 | 1 |
| Treatment Usage Patterns | 24 | 1 |
| Diseased Population | 25 | 1 |
| Treatment Seeking Population | 25 | 1 |
| Diagnosed Population | 25 | 1 |
| Prescription Population | 26 | 1 |
| Top Five Countries of Europe | 27 | 1 |
| Revenue | 27 | 1 |
| Revenue by Country | 28 | 2 |
| Annual Cost of Treatment | 30 | 1 |
| Treatment Usage Patterns | 31 | 1 |
| Diseased Population | 32 | 1 |
| Treatment Seeking Population | 32 | 1 |
| Diagnosed Population | 32 | 1 |
| Prescription Population | 32 | 1 |
| Japan | 33 | 1 |
| Revenue | 33 | 1 |
| Annual Cost of Treatment | 34 | 1 |
| Treatment Usage Patterns | 35 | 1 |
| Diseased Population | 36 | 1 |
| Treatment Seeking Population | 36 | 1 |
| Diagnosed Population | 36 | 1 |
| Prescription Population | 36 | 1 |
| Musculoskeletal Disorders Therapeutics Market to 2017 - Therapeutic Landscape | 37 | 61 |
| Rheumatoid Arthritis Therapeutics Market | 37 | 1 |
| Introduction | 37 | 1 |
| Revenue | 37 | 1 |
| Revenue by Country | 38 | 2 |
| Branded vs. Generics | 40 | 1 |
| Annual Cost of Treatment | 41 | 1 |
| Treatment Usage Pattern | 42 | 2 |
| Diseased Population | 44 | 1 |
| Treatment Seeking Population | 45 | 1 |
| Diagnosed Population | 46 | 1 |
| Prescription Population | 47 | 1 |
| Treatment Flow Algorithm | 48 | 1 |
| Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market | 48 | 1 |
| Drivers for the Rheumatoid Arthritis Therapeutics Market | 48 | 1 |
| Barriers for the Rheumatoid Arthritis Therapeutics Market | 49 | 1 |
| Osteoporosis Therapeutics | 50 | 1 |
| Introduction | 50 | 1 |
| Revenue | 50 | 1 |
| Revenue by Country | 51 | 2 |
| Branded vs. Generics | 53 | 1 |
| Annual Cost of Treatment | 54 | 1 |
| Treatment Usage Patterns | 55 | 1 |
| Diseased Population | 56 | 1 |
| Treatment Seeking Population | 57 | 1 |
| Diagnosed Population | 58 | 1 |
| Prescription Population | 59 | 1 |
| Treatment Flow Algorithm | 60 | 1 |
| Drivers and Barriers for Osteoporosis Therapeutics Market | 60 | 1 |
| Drivers for Osteoporosis Therapeutics Market | 60 | 1 |
| Barriers for Osteoporosis Therapeutics Market | 61 | 1 |
| Osteoarthritis Therapeutics | 62 | 1 |
| Introduction | 62 | 1 |
| Revenue | 62 | 1 |
| Revenue by Country | 63 | 2 |
| Branded vs. Generics | 65 | 1 |
| Annual Cost of Treatment | 66 | 1 |
| Treatment Usage Patterns | 67 | 1 |
| Diseased Population | 68 | 1 |
| Treatment Seeking Population | 69 | 1 |
| Diagnosed Population | 70 | 1 |
| Prescription Population | 71 | 1 |
| Treatment Flow Algorithm | 72 | 1 |
| Drivers and Barriers for Osteoarthritis Therapeutics Market | 72 | 1 |
| Drivers for Osteoarthritis Therapeutics Market | 72 | 1 |
| Barriers for Osteoarthritis Therapeutics Market | 73 | 1 |
| Low Back Pain Therapeutics | 74 | 1 |
| Introduction | 74 | 1 |
| Revenue | 74 | 2 |
| Revenue by Country | 76 | 2 |
| Branded vs. Generics | 78 | 1 |
| Annual Cost of Treatment | 79 | 1 |
| Treatment Usage Patterns | 80 | 1 |
| Diseased Population | 81 | 1 |
| Treatment Seeking Population | 82 | 1 |
| Diagnosed Population | 83 | 1 |
| Prescription Population | 84 | 1 |
| Treatment Flow Algorithm | 85 | 1 |
| Drivers and Barriers for Low Back Pain Therapeutics Market | 86 | 1 |
| Drivers for Low Back Pain Therapeutics Market | 86 | 1 |
| Barriers for Low Back Pain Therapeutics Market | 86 | 1 |
| Muscular Dystrophy Therapeutics | 87 | 1 |
| Introduction | 87 | 1 |
| Revenue | 87 | 1 |
| Revenue by County | 88 | 2 |
| Annual Cost of Treatment | 90 | 1 |
| Treatment Usage Patterns | 91 | 1 |
| Diseased Population | 92 | 1 |
| Treatment Seeking Population | 93 | 1 |
| Diagnosed Population | 94 | 1 |
| Prescription Population | 95 | 1 |
| Treatment Flow Algorithm | 96 | 1 |
| Drivers and Barriers for Muscular Dystrophy Therapeutics Market | 96 | 1 |
| Drivers for Muscular Dystrophy Therapeutics Market | 96 | 1 |
| Barriers for Muscular Dystrophy Therapeutics Market | 97 | 1 |
| Musculoskeletal Disorders Therapeutics Market to 2017 - Pipeline Analysis | 98 | 32 |
| Introduction | 98 | 2 |
| Musculoskeletal Disorders Therapeutics Market Pipeline Assessment by Clinical Phase of Development | 100 | 1 |
| NDA Filed Molecules | 100 | 2 |
| Phase III | 102 | 11 |
| Phase II | 113 | 4 |
| Phase I | 117 | 2 |
| Preclinical Phase | 119 | 4 |
| Discovery Phase | 123 | 2 |
| Profiles of Promising Molecules in the Musculoskeletal Disorders Therapeutics Market | 125 | 1 |
| YM529 (minodronate) | 125 | 1 |
| Introduction | 125 | 1 |
| Mechanism of Action | 125 | 1 |
| Clinical Trial Management | 125 | 1 |
| EX101 (alendronate) | 125 | 1 |
| Introduction | 125 | 1 |
| Mechanism of Action | 125 | 1 |
| Clinical Trial Management | 126 | 1 |
| MAbThera (rituximab) | 126 | 1 |
| Introduction | 126 | 1 |
| Mechanism of Action | 126 | 1 |
| Clinical Trial Management | 126 | 1 |
| Actemra (tocilizumab) | 127 | 1 |
| Introduction | 127 | 1 |
| Mechanism of Action | 127 | 1 |
| Clinical Trial Management | 127 | 1 |
| Simponi | 128 | 1 |
| Introduction | 128 | 1 |
| Mechanism of Action | 128 | 1 |
| Clinical Trial Management | 128 | 1 |
| Naproxcinod | 128 | 1 |
| Introduction | 128 | 1 |
| Mechanism of Action | 128 | 1 |
| Clinical Trial Management | 129 | 1 |
| Iguratimod | 129 | 1 |
| Introduction | 129 | 1 |
| Mechanism of Action | 129 | 1 |
| Clinical Trial Management | 129 | 1 |
| Musculoskeletal Disorders Therapeutics Market to 2017 - Competitive Profiling | 130 | 6 |
| Competitive Profiling | 130 | 1 |
| Abbott Laboratories | 130 | 1 |
| Company Overview | 130 | 1 |
| Marketed Drugs | 130 | 1 |
| SWOT Analysis | 130 | 1 |
| Johnson &Johnson | 131 | 1 |
| Company Overview | 131 | 1 |
| Marketed Drugs | 131 | 1 |
| SWOT Analysis | 131 | 1 |
| Amgen Inc. | 132 | 1 |
| Company Overview | 132 | 1 |
| Marketed Drugs | 132 | 1 |
| SWOT Analysis | 132 | 1 |
| Pfizer Inc | 133 | 1 |
| Company Overview | 133 | 1 |
| Marketed Drugs | 133 | 1 |
| SWOT Analysis | 134 | 1 |
| Eli Lilly and Company | 134 | 1 |
| Company Overview | 134 | 1 |
| Marketed Drugs | 134 | 1 |
| SWOT Analysis | 135 | 1 |
| Musculoskeletal Disorders Therapeutics Market to 2017 - Strategic Consolidations | 136 | 17 |
| Mergers and Acquisitions | 136 | 3 |
| Segmentation by Deal Value | 139 | 3 |
| Segmentation by Geography | 142 | 1 |
| Co-development Deals | 143 | 2 |
| Summary of Co-development Deals | 145 | 1 |
| Takeda Enters Into Co-Development Agreement with Covance in 2011 | 145 | 1 |
| Takeda Enters Into Co-Development Agreement with Quintiles in 2011 | 145 | 1 |
| Lycera Enters Into Research Agreement with Merck in 2011 | 145 | 1 |
| Radius Healthe Enters Into Collaboration Agreement with 3M Drug Delivery Systems in 2011 | 146 | 1 |
| Abbott Laboratories Enters Into Co-Development Agreement with Biotest for BT-061 in 2011 | 146 | 1 |
| Licensing Deals | 147 | 3 |
| Summary of Licensing Deals | 150 | 1 |
| XOMA Enters Into Licensing Agreement with Les Laboratoires Servier For XOMA 052 in 2011 | 150 | 1 |
| Viropro Enters Into Licensing Agreement with Spectrum Pharmaceuticals for Rituximab in 2011 | 150 | 1 |
| MedImmune Enters Into Licensing Agreement with Amgen for AMG 108 in 2011 | 151 | 1 |
| Harbor BioSciences Enters Into Licensing Agreement with China State Institute of Pharmaceutical in 2011 | 151 | 1 |
| Synta Pharmaceuticals Extends Its Licensing Agreement with Roche in 2011 | 151 | 1 |
| SuppreMol Enters Into Licensing Agreement with Bayerische in 2011 | 151 | 1 |
| Emergent BioSolutions Amends Licensing Agreement with Pfizer in 2011 | 152 | 1 |
| Hanwha Chemical Enters Into Licensing Agreement with Merck for HD203 in 2011 | 152 | 1 |
| Synta Pharmaceuticals Extends Licensing Agreement with Roche in 2011 | 152 | 1 |
| Musculoskeletal Disorders Therapeutics Market to 2017 - Appendix | 153 | 7 |
| Market Definitions | 153 | 1 |
| Abbreviations | 153 | 1 |
| Research Methodology | 154 | 2 |
| Coverage | 154 | 1 |
| Secondary Research | 154 | 1 |
| Primary Research | 155 | 1 |
| Therapeutic Landscape | 155 | 3 |
| Epidemiology-based Forecasting | 156 | 1 |
| Market Size by Geography | 157 | 1 |
| Geographical Landscape | 158 | 1 |
| Pipeline Analysis | 158 | 1 |
| Competitive Landscape | 158 | 1 |
| Expert Panel Validation | 158 | 1 |
| Contact Us | 158 | 1 |
| Disclaimer | 159 | 1 |
| Sources | 159 | 1 |